AstraZeneca said that the combination of its Imfinzi (durvalumab) monotherapy and tremelimumab has failed to improve overall survival (OS) rate compared to standard-of-care (SoC) chemotherapy in a head and neck cancer trial.
Novartis has initiated phase III trials for its monoclonal anti-IgE antibody ligelizumab (QGE031) in chronic spontaneous urticaria (CSU) patients whose symptoms are inadequately controlled by H1-antihistamines.
Data analytics company Ixico has signed an expanded scope to an existing contract with a top 10 biopharmaceutical company.
Johnson & Johnson’s (J&J) Darzalex (daratumumab), in combination with lenalidomide and dexamethasone (Rd), has significantly reduced the risk of disease progression in multiple myeloma study.
US-based Vedanta Biosciences has started a phase I clinical study of its live biotherapeutic product (LBP) candidate VE202 to treat inflammatory bowel disease (IBD).
Contract research organization (CRO) QPS has expanded its US-based phase I clinical trial capabilities to support the increasing requirements of its pharmaceutical, biotechnology and CRO partners.
Bristol-Myers Squibb (BMS) announced that its cancer drug combination Opdivo plus Yervoy has failed to improve overall survival (OS) rate in the phase 3 CheckMate -451 study.
Biopharmaceutical company Poxel has stared part 2 of the phase 1a study for PXL065, a deuterium-stabilized R-stereoisomer of pioglitazone.
Pfizer and Merck have announced that avelumab alone or in combination with pegylated liposomal doxorubicin (PLD) has failed to improve overall survival (OS) or progression-free survival (PFS) rate in phase III Javelin Ovarian 200 trial.
GlycoMimetics has dosed the first patient in its Phase 3 clinical trial of uproleselan (GMI-1271) in relapsed/refractory acute myeloid leukemia (AML).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.